IPHYF News Alert Innate Pharma (IPHYF) 9.6500 09/20/2014 17:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Innate Pharma (IPHYF) 9.6500 $IPHYF

INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
GlobeNewswire - Tue Sep 16, 11:40AM CDT
-- Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US

Innate Pharma SA concludes target enrollment of 150 Acute Myeloid Leukemia patients in EffiKIR trial
M2 - Fri Jul 25, 4:59AM CDT
Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) revealed on Thursday that it has completed target enrollment in the EffiKIR trial with 150 Acute Myeloid Leukemia (AML) patients randomised.

INNATE PHARMA : Completion of target enrollment in the phase II EffiKIR trial
GlobeNewswire - Thu Jul 24, 12:36AM CDT
-- Data on primary efficacy endpoint Leukemia-Free Survival expected end of 2015

Innate Pharma SA begins Phase I trial with lirilumab and nivolumab in selected solid tumors under cohort expansion
M2 - Mon Mar 31, 4:36AM CDT
Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) reported on Monday that it has started the cohort expansion portion of the Phase I clinical trial testing the combination of the two investigational checkpoint inhibitors lirilumab and nivolumab in selected solid tumors.

INNATE PHARMA : Start of cohort expansion of Phase I trial with lirilumab and nivolumab in selected solid tumors
GlobeNewswire - Mon Mar 31, 12:50AM CDT
Start of cohort expansion of Phase I clinical trial testing the combination of lirilumab and nivolumab in selected solid tumors

INNATE PHARMA : announces first DSMB review of ongoing EffiKIR Phase II trial with lirilumab
GlobeNewswire - Tue Sep 17, 1:34AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board ("DSMB" completed its first assessment of the EffiKIR study and unanimously recommended continuation of the trial without modification.

Cutaneous T-Cell Lymphoma - Latest Pipeline Review Report
M2 - Fri Jul 12, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q8vtbk/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2012" report to their offering. 'Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Scope - A snapshot of the global therapeutic scenario for Cutaneous T-Cell Lymphoma. - A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipel

Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013 Report
M2 - Wed Jun 19, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jbrmql/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013" report to their offering. "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication th

Sezary Syndrome - Pipeline Review, H1 2013 Contains Latest News and Deals Relating to the Products
M2 - Fri Jun 07, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2npr37/sezary_syndrome) has announced the addition of the "Sezary Syndrome - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Sezary Syndrome - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sezary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sezary Syndrome. Sezary Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Sezary Syndrom




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Early Therapy After Sports Injuries Deserves Careful Timing

Updated Category News Views 80

A limp can become a bad habit long before an athlete calls it one. That is the plain, useful concern behind Dr. Kali Spoto LaRue's discussion of sports-injury physical therapy for athletes in Fairport and Greater Rochester. The central message is not that every sore muscle needs the same response, nor that anybody should charge back into practice because they had one...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 56

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 114

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 51

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 146

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 189

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 16

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Carnival Maps a Longer, Broader Bet on Cruise Demand

Updated Category News Views 36

A cruise operator does not order ships for 2035 because it is feeling timid. Carnival is laying out a long runway of hardware, private-destination capacity and onboard-to-onshore spending hooks, all aimed at keeping guests inside its ecosystem longer. For NYSE:CCL, this is not a next-quarter story. It is a very public statement that management sees enduring appetite for...

Continue Reading
Specialized Metal Makers Become the New M&A Prize Again

Updated Category News Views 44

A forgotten heat-treatment line can suddenly be worth more than a shiny new mill when buyers realize nobody can duplicate its certifications, workforce, and customer approvals overnight. That is the basic truth sitting underneath BGL's Nov. 19, 2026 assessment of the U.S. metals market. The easy headline is consolidation. The useful takeaway is much narrower: specialized...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 17

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Expanding Scope of Implantable Medical Devices

Updated Category News Views 122

Overview of the Implantable Medical Devices Market The global market for implantable medical devices is witnessing remarkable growth, with projections estimating it to reach approximately USD 176.33 billion by 2034, escalating at a compound annual growth rate (CAGR) of 6.14%. This rise is largely influenced by a steadily increasing prevalence of chronic diseases and an...

Continue Reading
Revolutionizing Home Financing: The Launch of Rate Intelligence

Updated Category News Views 109

Rate's Innovative AI Solution for Mortgage Lending Rate, a pioneer in financial technology, has recently introduced Rate Intelligence—an advanced AI platform that seeks to redefine the mortgage experience for both homebuyers and loan officers. By leveraging cutting-edge technology, Rate is on a mission to enhance efficiency, speed, and accuracy in the home financing...

Continue Reading
Lindahl Reed Secures OASIS+ Contracts to Enhance Services

Updated Category News Views 163

Lindahl Reed Achieves Significant OASIS+ Contract Awards Lindahl Reed, Inc., a prominent player in the technical and scientific services arena, has recently been awarded the One Acquisition Solution for Integrated Services Plus (OASIS+) – 8(a) and Women-Owned Small Business (WOSB) Multi-Agency Contract master contracts. This new development is noteworthy as it allows...

Continue Reading
Safe Bulkers (NYSE: SB) Sees 52-Week Low Amid Market Struggles

Updated Category News Views 334

Safe Bulkers (NYSE: SB) Faces Market Challenges In a challenging environment for investors, Safe Bulkers Inc. (NYSE: SB) has witnessed its stock drop to a 52-week low, currently standing at $3.4. This decline highlights the broader issues prevalent in the shipping sector, where shifts in demand and fluctuating shipping rates have placed pressure on many companies,...

Continue Reading
Emerging Cybersecurity Trends for 2026: AI's Dual Role

Updated Category News Views 280

Understanding 2026: Cybersecurity Predictions and Insights In an era where technology is evolving at a rapid pace, organizations find themselves at a critical juncture. The proliferation of AI poses both unprecedented opportunities and significant threats. Businesses must stay vigilant against a historic wave of DNS exploitation alongside an evolving threat landscape. As...

Continue Reading